Marrone Bio Appoints Kevin Helash as Chief Executive Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Marrone Bio Innovations (MBII) Names Kevin Helash as CEO
July 6, 2020 4:09 PM EDTMarrone Bio Innovations, Inc., (NASDAQ: MBII) today announced the appointment of Kevin Helash as its new chief executive officer. Concurrent with joining the company, he will be appointed to serve as a member of the board of directors. Helash, 55, a native of Manitoba, Canada, will join the company as early as August 1, 2020. His effective date is pending receipt of permanent residency status or the applicable visa, both of which are in process.
A 28-plus-year agricultural industry veteran, Helash comes to Marrone Bio from Agrinos AS, a global-scale biological crop input provider specializing in... More
